Company profile
Omnimmune Holdings, Inc.
OTC: OMMH · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 27
v0.1 · 5/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$1.8M
Employees
2
as of 2026-07-19
Market cap
$981
as of 2026-07-19
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02009
Net income-$1.8M-$1.8M2009
Operating income-$1.5M-$1.5M2009
Total assets$31.4k$31.4k2009
Liabilities$5.5M$5.5M2009
Equity-$5.4M-$5.4M2009
Revenue trend
FY2006 – FY2009 · USD
FY06
FY07
FY08
FY09
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Omnimmune Holdings, Inc.’s revenue?
Omnimmune Holdings, Inc. booked $0 in FY2009 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
CVR Medical Corp.——Lynx Global Digital Finance Corporation——Grupo International Inc.——TetraLogic Pharmaceuticals Corporation——BioELife Corp.——Rapid Therapeutic Science Laboratories, Inc.——Neighbors
Harris →Key facts
CEOSaul Leal
SectorHealthcare
IndustryBiotechnology
HeadquartersHouston, TX
ExchangeOTC: OMMH
Employees2
IPO date2007-12-19
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.